TC BioPharm Announces Pricing of $5.5 Million Public Offering

EDINBURGH, Scotland, March 28, 2023 /PRNewswire/ — TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the pricing of a public offering of…

No Comments

No comments yet.

Sorry, the comment form is closed at this time.